Abstract
The National Institute for Health and Clinical Excellence (NICE) is producing guidance on using the PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites in the NHS in England. The Medical Technologies Advisory Committee has considered the evidence submitted and the views of expert advisers.
Summary of findings
- The case for adopting the PleurX peritoneal catheter drainage system in the NHS is supported by the evidence. The available clinical evidence suggests that the PleurX peritoneal catheter drainage system is clinically effective, has a low complication rate and has the potential to improve quality of life.
- The PleurX peritoneal catheter drainage system should be considered for use in patients with treatment-resistant, recurrent malignant ascites.
- The PleurX peritoneal catheter drainage system is associated with an estimated cost saving of £679 per patient when compared with inpatient large-volume paracentesis.
This public consultation document does not form NICE’s final guidance and the organisation points out that the recommendations may change after consultation. After consultation the Committee will meet again to consider the evidence, this document and comments from public consultation. After considering these comments, the Committee will prepare its final recommendations which will be the basis for NICE’s guidance on the use of the technology in the NHS in England.
Source: NICE
published: November 24, 2011 in: Economics, General Surgery, Healthcare, Regulatory